We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies
12 Dec 2025 - Baar, 12 December 2025 – PolyPeptide Group AG (SIX: PPGN), a global CDMO for peptide-based APIs, and Lupin Manufacturing Solutions Limited (LMS) have formed a strategic […]
Read morePolyPeptide Group achieves significant milestone in Malmö expansion project
22 Sep 2025 - Baar, 22 September 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful delivery and installation […]
Read morePolyPeptide announces expansion of existing credit facilities
23 May 2025 - Baar, 23 May 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced that it has secured additional […]
Read morePolyPeptide announces results of the annual General Meeting 2025
9 Apr 2025 - Baar, 9 April 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2025
18 Mar 2025 - Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth […]
Read moreCytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs
13 Jan 2025 - This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address […]
Read moreDoubling of production capacity at the manufacturing site in Malmö
8 Jan 2025 - Baar, 8 January 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the planned doubling of solid-phase peptide […]
Read moreLarge-scale SPPS capacity in Braine-l’Alleud starts production
16 Dec 2024 - Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the […]
Read morePolyPeptide appoints Chief Commercial Officer
8 Aug 2024 - Baar, 8 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of […]
Read more